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Pateamine A inhibits translation by preventing proper translational initiation complex formation.
In the December issue of Chemistry & Biology, Bordeleau et al. demonstrated that the effects of
Patemine A on translation are mediated through the interaction between the RNA helicase eIF4A
and mRNA [1].Many aspects of malignantly trans-
formed phenotypes are due to the dys-
regulation of translation. The switch
from normal growth to either malignant
transformation or apoptosis is deter-
mined by the spectrum of mRNAs
that are translated. Many growth-pro-
moting and apoptotic mRNAs are
poorly translated under normal physio-
logical conditions, due to factors such
as a highly structured 50-untranslated
region (UTR) or an internal ribosomal
entry site (IRES). Translation of most
cellular mRNA, and especially those
which contain a highly structured 50-
UTR or an IRES, depends on the integ-
rity and activity of the eIF4F complex,
consisting of eIF4A, eIF4E, and eIF4G.
eIF4G functions as the pivotal factor,
acting through direct interactions with
mRNA, eIF4E, eIF4A andanother initia-
tion factor, eIF3, and providing a link
between the mRNA and the 40S ribo-
somal subunit. The recruitment of
mRNA to the 40S ribosomal subunit
to form the 48S initiation complex is
catalyzed by the eIF4 group of factors:
eIF4B, eIF4F, and eIF4H. eIF4F recog-
nizes the cap structure at the 50-end of
mRNA through eIF4E, unwinds the
secondary structure of the 50-UTR re-
gion through the helicase activity of
eIF4A, and binds the 43S complex
through interactions between eIF4G
and eIF3 (Figure 1A). eIF4H and eIF4B
increase the processivity of eIF4A
(reviewed in [2]).
Pateamine A (PatA) is an immuno-
suppressive and antiproliferative agent
that was isolated from the marine
sponge Mycale sp. PatA was found to
induce apoptosis in certain mamma-
lian cell lines, especially those that
were transformed by either ras or bcr-abl oncogenes [3]. PatA affects both
transcriptional and translational pro-
cesseswith thegreater inhibitory effect
being on translation [4, 5]. At concen-
trations less than 0.1 mM, PatA inhib-
its proliferation of cancer cells, sup-
presses cap-dependent and eIF4G-
dependent IRES-driven translation,
disrupts polysomes, and induces
stress granule formation [4, 6, 7]. The
ability of PatA to induce apoptosis in
transformed cells but not in normal
cells suggests that is has therapeutic
potential in cancer treatment.
MALDI-TOFmass spectrometry and
immunological analysis have identified
eIF4A as the biological target of PatA
[4, 8]. eIF4A is a bidirectional RNA heli-
case. It binds to and unwinds RNA in
an ATP-dependent manner and hydro-
lyzes ATP in an RNA-dependent man-
ner. It is the prototype for the DEAD/H-
box protein family and contains at
least nine motifs conserved in nucleic
acid helicases. In contrast to other hel-
icases, eIF4A does not have extra do-
mains that regulate substrate specific-
ity or stimulate strand separation.
eIF4A alone is aweak ATPase and heli-
case, but these activities are stimu-
lated by eIF4G, eIF4B, and eIF4H, sug-
gesting that they supply the missing
functions (reviewed in [9]). There are
three eIF4A family members in mam-
mals. eIF4AI and eIF4AII are both in-
volved in RNA unwinding during the
initiation of translation as a part of the
eIF4F complex. eIF4AIII is a nucleocy-
toplasmic shuttling protein associated
with the exon junction complex and
is essential for nonsense-mediated
mRNA decay [10]. Pelletier and col-
leagues have previously shown that
all three eIF4A family members areChemistry & Biology 14, January 2007captured from HL-60 cell extracts by
a PatA-affinity resin and that PatA af-
fects translation by specifically target-
ing free eIF4A [8]. During mRNA un-
winding, eIF4A cycles between the
eIF4F complex and the free eIF4A
pool [11, 12], a process that is critical
for the unwinding of mRNA. Interest-
ingly, PatA stimulates the intrinsic
ATPase andhelicase activities of eIF4A
rather than inhibiting them, by stabiliz-
ing the eIF4A:mRNA complex [8].
A new observation made by Pelletier
and co-workers [1] is that eIF4A-mRNA
stabilization allows attachment of ad-
ditional factors to mRNA. Western blot
analysis of eIF4A distribution through-
out a sucrose gradient revealed the
sedimentation of eIF4A in complexes
larger than 48S in the presence of
PatA [4]. The observation that such
eIF4A sedimentation was sensitive to
nuclease treatment [1] further supports
the idea that, in the presence of PatA,
eIF4A is part of complexes containing
mRNA as well as other mRNA binding
proteins. The authors suggest that the
sequestration of eIF4A in new mRNA-
protein complexes limits the availabil-
ity of eIF4A for incorporation into
eIF4F complex (Figure 1B).
One protein that interacts with the
eIF4A:mRNA complex through the
mRNA component is eIF4B [1]. eIF4B
has been shown to interact with two
different mRNA molecules simulta-
neously and to anneal complementary
RNA strands. It may also facilitate
binding of the 40S ribosomal subunit
to mRNA [13]. The central part of
mammalian eIF4B contains a DRYG
motif, which facilitates its homodimeri-
zation and binding to eIF3. It has been
suggested that in addition to bindingª2007 Elsevier Ltd All rights reserved 5
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(A) 48S complex formation under normal conditions.
(B) Pateamine A sequesters eIF4A from eIF4F and stabilizes eIF4A on mRNA preventing 48S com-
plex formation.
(C) Pateamine A induces aberrant, eIF4F-independent 48S initiation complexes that load at ran-
dom locations on mRNA and prevent translation.mRNA and stimulating the helicase ac-
tivity of eIF4A, eIF4B serves as a bridge
between eIF3 and the 40S subunit [13].
Since eIF4A is one of the most abun-
dant initiation factors in the cell (3 to
50 mM, depending on the cell type)
[14, 15], it is likely that the 10-20 nM
PatA that is capable of disrupting poly-
somes in vivo does so not only by lim-
iting the pool of free eIF4A that is re-
cycled through eIF4F, but also by
producing aberrant eIF4F-indepen-
dent 48S initiation complexes that
load at random locations on mRNA
and prevent its translation (Figure 1C).
A previous study showed that high
concentrations of PatA (10 mM and
higher)preventscopurificationofeIF4A
and eIF4G from cell lysates [4]. The re-
cent data obtained by Bordeleau et al.
[1] with pull-down and FRET assays
showed that 10 mM PatA did not affect6 Chemistry & Biology 14, January 2007 ªthe direct binding of eIF4A to eIF4G
variants containing only one of the
two eIF4A binding sites. By contrast,
the same concentration of PatA pre-
vented incorporation of recombinant
eIF4A into eIF4F bound to m7GTP-
Sepharose. Since the latter experiment
used the ribosomal high-salt wash as
a source of eIF4F, which may contain
additional RNA binding proteins and
mRNA, it is possible that PatA stabili-
zation of either the eIF4A:mRNA or
eIF4A:mRNA-protein complexes pre-
vented the incorporation of eIF4A into
eIF4F.
There is a discrepancy in the effect
that a high concentration of PatA has
on the stability of the 48S complex.
Low et al. [4] found that 100 mM PatA
stabilized or even increased the level
of radiolabeled mRNA incorporated
into the 48S complex and interpreted2007 Elsevier Ltd All rights reservedthis as being the result of stalled 48S
ribosome initiation complexes. In con-
trast, Bordeleau et al. [8] and [1] ob-
served the reduction of 48Scomplexes
upon treatmentwith 10mMPatA,which
they interpret as being due to the se-
questration of eIF4A from eIF4F. They
suggest that the observeddiscrepancy
is due to differences in the source
of PatA.
Despite this discrepancy, the obser-
vation that theeffects ofPatAaremedi-
ated by the interaction between eIF4A
and mRNA is important. A detailed
understanding of the mechanism by
which PatA inhibits translation should
facilitate the development of chemo-
theraputic agents based on PatA. In
particular, the observation that PatA
acts through eIF4A suggests that it
may be particularly useful in treating
cancers in which eIF4A is either over-
expressed or hyperactivated [16].
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Before the genomics revolution, the
isolation of new natural products relied
exclusively on the detection of bio-
activity in extracts fromnatural sources
oronphysico-chemicalproperties, e.g.,
the presence of a chromophore. Purifi-
cation of compounds identified in
these ways was achieved by assay-
guided fractionation. The most ex-
plored bioactivity assay targeted anti-
biotic activity. Using this approach,
penicillin was isolated from Penicillium
notatum, sparking the ‘‘Golden Age
of Antibiotics,’’ which spanned the
1940s to the 1970s. During this pe-
riod, the pharmaceutical industry was
deeply engaged in the search for new
natural products. At the end of the
20th century, the supply of new natural
products from this assay-guided ap-
proach appeared to be almost ex-
hausted,mainlybecauseknownnatural
products were rediscovered with high
frequency [2].
With the new century, the power of
genomics generated new methodo-
logies for isolating novel natural prod-
ucts. Indeed, the large quantity of
publicly accessible DNA sequence
data opened the way for exploitation
of bioinformatics tools for new natural
product discovery. Using these tools,
several microbial genomes have been
found to contain so-called ‘‘cryptic’’
or ‘‘orphan’’ gene clusters encoding
putative biosynthetic enzymes likely
to be involved in the production of un-13. Methot, N., Pickett, G., Keene, J.D., and
Sonenberg, N. (1996). RNA 2, 38–50.
14. Rau, M., Ohlmann, T., Morley, S.J., and
Pain, V.M. (1996). J. Biol. Chem. 271,
8983–8990.Genome Mining
hallis1,*
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ogy, Gross et al. [1] report develop
f orphan biosynthetic gene cluste
ide A, a novel cyclic lipopeptide.
knownandpotentially novel secondary
metabolites [3–7]. The putative func-
tion and substrate specificity of some
of these proteins, e.g., modular nonri-
bosomal peptide synthetase (NRPS)
and polyketide synthase (PKS) multi-
enzymes could also be predicted. Ge-
nome mining for novel nonribosomal
peptide natural products began in
2000, when a cryptic NRPS encoded
within the Streptomyces coelicolor A3(2)
genome sequence was discovered
and the substrate specificity of this
system was predicted [9], allowing
physicochemical properties of the me-
tabolite to be proposed. Using a gene
knockout/comparative metabolic pro-
filing strategy (Figure 1), the product
of this NRPS—coelichelin—was dis-
covered [8]. In the last three years, the
discovery of several novel polyketides
and terpenoids by genomemining em-
ploying a variety of approaches (Fig-
ure 1) has been reported [7, 10–16, 19].
In this issue of Chemistry & Biology,
Gross et al. report the development of
a new tool for genome mining that
promises to significantly expand the
current armamentarium (Figure 1, red
box), and its application to the isolation
of a novel bioactive nonribosomal
peptide product of an orphan gene
cluster identified in the Pseudomonas
fluorescens Pf-5 genome sequence
[1]. Bioinformatics tools predicted the
substrate specificity of the NRPS en-
coded within the gene cluster, leading
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Zheng, X.,Merrick,W.C., Costes, S., Lock-
ett, S.J., Sonenberg, N., and Colburn, N.H.
(2003). Mol. Cell. Biol. 23, 26–37.ment of a novel genome mining
rs, and the application of this
to thehypothesis that it directs produc-
tion of a novel lipopeptide containing
four leucine residues. This hypothesis
led to the idea of using 1H-15N HMBC
NMR spectroscopy to guide its purifi-
cation from cultures of P. fluorescens
fed with 15N-labeled leucine, dubbed
‘‘the genomisotopic approach’’ by the
authors. A traditional bioassay-guided
purification was also set up in parallel.
Both approaches resulted in the iso-
lation of orfamide A, along with minor
amounts of two analogs.
The novelty of the genomisotopic
approach resides in the combination
of predictions from genomics with the
exploitation of stable-isotope-labeled
precursor incorporation. Since the
advent of routine multinuclear NMR
spectroscopy in 1970s, stable-isotope
labeled precursors have beenpowerful
tools for investigating the biosynthetic
origins of natural products. However
developments in our understanding of
the genetics andenzymologyof natural
product biosynthesis in recent years
have been accompanied by a decline
in the use of stable isotopes to investi-
gate biosynthetic pathways.
The genomisotopic approach is a
potentially quite general genome min-
ing tool for the isolation of new non-
ribosomal peptide natural products,
because at least some of the sub-
strates of NRPSs with known se-
quence, but unknown function, can
be predicted with a reasonable degree
ª2007 Elsevier Ltd All rights reserved 7
